Claims:

Claim 1. Use of a glucagon-like-peptide-2 (GLP-2) analogue in the manufacture of a medicament for treatment of short bowel syndrome (SBS) in a human subject receiving a parenteral support (PS) regimen, wherein a volume of the parenteral support regimen is to be reduced each week whereby:

(i) the GLP-2 analogue is to be administered for a time sufficient to grow and/or improve the function of the small intestine of the subject;

(ii) the volume of the parenteral support (PS) regimen is to be reduced in response to improved function of the small intestine; and

wherein:

(a) a baseline urine volume is to be determined at the start of the GLP-2 therapy and/or a daily urine volume of the subject is to be determined;

(b) a current weekly volume of PS required by the subject at that point in the treatment is to be determined;

(c) an absolute increase in urine production per day is to be determined by comparing a current urine volume produced by the subject to the baseline urine volume determined at the start of the GLP-2 therapy; and

(d) the volume of the PS is to be reduced where the absolute increase in urine production per day is observed;

wherein a new reduced weekly calculated PS volume for the subject equals the current weekly PS volume minus 7 times the absolute increase in daily urine volume from the baseline urine volume.

Claim 2. The use of claim 1, wherein the volume of the PS is to be reduced if the daily urine volume is at least 10% higher than baseline urine volume.

Claim 3. The use according to claim 1 or 2, wherein the GLP-2 analogue comprises a GLP-2 analogue represented by the formula:

R^1-Z^1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z^2-R^2

wherein:

R^1 is hydrogen, C_{1-4} alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;

X5 is Ser or Thr;

X11 is Ala or Ser;

R^2 is NH_2 or OH; and

Z^1 and Z^2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;

or a pharmaceutically acceptable salt thereof.

Claim 4. The use according to any one of the preceding claims, wherein the GLP-2 analogue is formulated to be administered to the patient once or twice weekly.

Claim 5. The use according to any one of the preceding claims, wherein the new reduced weekly calculated PS volume for the subject is to be calculated at one or more points during the course of the GLP-2 therapy received by the subject.

Claim 6. The use according to any one of the preceding claims, wherein the new reduced weekly calculated PS volume is to be calculated within 2, 3, 4, 5, 6 or 7 days after start of the GLP-2 therapy.

Claim 7. The use according to any one of the preceding claims, wherein the new reduced weekly calculated PS volume is to be calculated 1, 2, 3, 4, 5, 6 or 7 weeks after start of the GLP-2 therapy.

Claim 8. The use according to any one of the preceding claims, wherein the risk of adverse effect of a to high PS volume is to be reduced, optionally wherein the adverse effect is fluid overload.

Claim 9. The use according to any one of claims 3 to 8, wherein X5 is Thr and/or X11 is Ala.

Claim 10. The use according to claim 9, wherein the GLP-2 analogue is:

ZP1848 H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH_2,

ZP2949 H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKK-OH,

ZP2711 H-HGEGTFSSELATILDALAARDFIAWLIATKITDKK-OH,
ZP2469 H-HGEGTFSSELATILDALAARDFIAWLIATKITDK-OH,
ZP1857 H-HGEGTFSSELATILDALAARDFIAWLIATKITD-NH_2, or
ZP2530 H-HGEGTFSSELATILDALAARDFIAWLIATKITD-OH.

Claim 11. The use according to claim 9 or claim 10, wherein the GLP-2 analogue is:

ZP1848 H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH_2

Claim 12. The use according to any one of claims 3 to 8, wherein X5 is Ser and/or X11 is Ser.

Claim 13. The use according to claim 12, wherein the GLP-2 analogue is:

ZP1846 H-HGEGSFSSELSTILDALAARDFIAWLIATKITDKKKKKK-NH_2,
ZP1855 H-HGEGSFSSELSTILDALAARDFIAWLIATKITD-NH_2, or
ZP2242 H-HGEGSFSSELSTILDALAARDFIAWLIATKITDK-OH.

Claim 14. The use according to claim 13, wherein the GLP-2 analogue is:

ZP1846 H-HGEGSFSSELSTILDALAARDFIAWLIATKITDKKKKKK-NH_2

Claim 15. The use according to any one of the preceding claims, wherein the GLP-2 analogue is formulated to be administered in a fixed dose of 2 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9, mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg or 15 mg, once or twice weekly.

Claim 16. The use according to any one of the preceding claims, wherein the GLP-2 analogue is formulated to be administered in a fixed dose of 10 mg, once or twice weekly.

Claim 17. The use according to any one of claims 1 to 15, wherein the GLP-2 analogue is formulated to be administered in a fixed dose of 2 mg, once or twice weekly.